Pluto aims to build the next generation of “off-the-shelf” cellular immunotherapies.


We aim to change the way cancer is treated through unlimited in vitro production of tumor-optimized, functionally enhanced allogenic T cells. The projected market size for allogeneic cell therapy has been estimated as $~10.25B USD.


Our platform system is the best-in-class for the generation of mature T cells from pluripotent stem cells (PSC). Only PSC can generate off-the-shelf products with the optimal complex gene edits required for targeting solid tumors.


  • Best-in-class technology for generating mature T cells from a renewable source of induced pluripotent stem cells (iPSC)
  • Unlimited cell source
  • Unique potential for unlimited gene editing to engineer safer and more effective T cell therapies

Development Stage:

  • Pre-clinical

Select Publications: